FDA WARNING_LETTER - AAL Trading Inc. - May 27, 2026

The Food and Drug Administration (FDA) issued a warning letter to AAL Trading Inc. following an inspection from May 18 to May 27, 2026, at its Linden, New Jersey facility. The inspection sought to determine the company"s compliance with Foreign Supplier Verification Program (FSVP) requirements under Section 805 of the Federal Food, Drug, and Cosmetic Act. The primary violation identified was the company"s failure to develop, maintain, and follow an FSVP for its imported products, specifically Enoki and Maitake mushrooms from various foreign suppliers. As an importer, AAL Trading Inc. is required to perform risk-based activities to verify that foreign-produced food meets U.S. safety standards, including the Produce Safety Rule. Although the company provided an initial response regarding the location and language of its records, the FDA found it insufficient as no actual FSVP documentation was submitted for review. The FDA has mandated that the company provide a written response within 15 working days detailing its corrective actions and providing evidence of compliance. Failure to address these violations may result in the FDA refusing entry of the company"s imports or placing products on detention without physical examination.